

Yi-Chi-Tsung-Ming-Tang Reduced A β (1-40)-induced Neurotoxicity via of Acetylcholine and NMDA Receptors Expression, ROS Generation and Tau Phosphorylation

C. H. YE^{1,2}, H. C. HUANG³, K. S. CHANG⁴, C. J. CHEN³, M. L. YANG⁵, S. L. TSAI, H. W. LIN^{6,7} AND Y. H. KUAN^{8,9*}

Department of Sport and Health Management, College of Nursing and Health, Da-Yeh University, ¹Department of Neurology, Yuan Rung Hospital, Changhua, ²Department of Nursing, College of Medicine and Nursing, Hung-Kuang University, ³Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources; College of Pharmacy, China Medical University, Taichung, ⁴Department of Cardiology, Yuan Rung Hospital, Changhua, ⁵Department of Anatomy, School of Medicine, Chung Shan Medical University, ⁶Department of Optometry, Asia University, ⁷Department of Medical Research, China Medical University Hospital, China Medical University, ⁸Department of Pharmacology, School of Medicine, Chung Shan Medical University, ⁹Department of Pharmacy, Chung Shan Medical University Hospital, Taichung, Taiwan

Kuan, *et al*: YCTMT Reduced A β (1-40) Injury of Cortical Neurons

Yi-Chi-Tsung-Ming-Tang is a traditional Chinese medicine formula often prescribed for preventing or treating dizziness, tinnitus, mental fatigue and blurred vision. Recent study has demonstrated that A β (1-40)-induced neurotoxicity could be improved by this drug. The aim of present study was to determine the effects and protective mechanism of *Yi-Chi-Tsung-Ming-Tang* on A β (1-40)-induced death of primary cortical neurons. Primary cultures of Sprague-Dawley rat cortical neurons were exposed to A β (1-40), after the treatment with *Yi-Chi-Tsung-Ming-Tang* for 1 h. Methyl-thiazolyl-tetrazolium reduction assays were used to detect cell viability and the expression of acetylcholine receptors, N-methyl-D-aspartate receptors and phosphorylated and non-phosphorylated forms of tau were measured by western blot. Fluorometric assays were applied to detect the generation of reactive oxygen species. Pretreatment of primary cortical neurons with *Yi-Chi-Tsung-Ming-Tang* significantly inhibited A β (1-40)-induced cytotoxicity and reversed A β (1-40)-induced β -amyloid accumulation and acetylcholine receptor expression in a concentration-dependent manner. In addition, not only the A β (1-40)-reduced expression of N-methyl-D-aspartate receptors 1/2A was reversed but also the A β (1-40)-induced reactive oxygen species generation and tau phosphorylation expression were inhibited by *Yi-Chi-Tsung-Ming-Tang* in a concentration-dependent manner.

Key words: *Yi-Chi-Tsung-Ming-Tang*, A β , reactive oxygen species, tau, NMDARs

Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disease characterized by the loss of memory, which results in dementia, cognitive defect, behavioural disturbance and neuropsychiatric symptoms^[1]. A report published in 2006 had shown that 26.6 million people were affected by AD and approximately \$156 billion were spent annually on caring for AD patients worldwide. By the year of 2050, the prevalence of AD is expected to quadruple and shall place a considerable burden about health cost on society^[2]. Up to now, the drug treatment for AD mainly evolved around two mechanisms, which involved the inhibitors of acetyl cholinesterase and the stimulators of N-methyl-D-aspartate receptors (NMDAR). Unfortunately, these drugs do not much improve the symptoms caused by AD^[3].

The neuropathological hallmarks of AD contain

amyloid-beta (A β) aggregation, cerebral amyloid angiopathy, neurofibrillary tangles formation, neuron death, and synaptic loss^[4]. A β is the peptide fragment derived from an integral membrane protein, the amyloid precursor protein (APP), by secretases processing. A β (1-40) is one of the A β isoforms and the most abundant variant *in vivo*^[5,6]. A β and its derived oligomeric species can bind to NMDAR thus facilitating the endocytosis and activation of NMDAR. In addition, A β and its derived oligomers induce

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms

*Address for correspondence

E-mail: kuanyh@csmu.edu.tw

Accepted 23 April 2017

Revised 05 January 2017

Received 22 September 2016

Indian J Pharm Sci 2017;79(3):411-419

hyper phosphorylation of tau, which results in self-aggregation and microtubule destabilization. These molecule-associated pathogens, including up-regulated reactive oxygen species (ROS) generation and down-regulated acetylcholine receptor (AChR) expression, induce excitotoxicity in hippocampal and cortical neurons^[7,8].

Yi-Chi-Tsung-Ming-Tang (YCTMT) is a traditional Chinese medicine formula and presented by the Chinese physician, Dong-Yuan Li, in Jin Dynasty (AD 1200s). In traditional medicine, YCTMT has been used to prevent symptoms such as dizziness, tinnitus, deafness, mental fatigue, and blurred vision^[9-11]. In a previous study, we have demonstrated that YCTMT has a therapeutic effect on AD induced by A β (1-40) *in vivo*^[12]. In the present, we aimed to study the molecular mechanism and protective effects of YCTMT on A β (1-40)-induced cytotoxicity in cultured primary cortical neurons.

MATERIALS AND METHODS

YCTMT is composed of *Astragalus membranaceus* (Fisch.) Bunge, *Ginseng quinquefolium* (L.) Alph. Wood, *Pueraria lobata* (Willd.) Ohwi, *Paeonia lactiflora* Pall, *Phellodendron chinense* C.K.Schneid, *Vitex rotundifolia* L.f., *Cimicifuga foetida* L. and *Glycyrrhiza uralensis* Fisch. in a ratio of 5:5:5:1:1:1.5:3:5 (dry weight). All components were purchased from a Chinese herbal shop in Taichung, Taiwan and were certified at the Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan. Voucher specimens (No. 2011YCTMT-A~H) have been deposited at the China Medical University. A β (1-40) was purchased from Tocris Bioscience (Ellisville, MO, USA) and dissolved in a vehicle containing 35% acetonitrile and 0.1% trifluoroacetic acid. Glycyrrhizin was purchased from Tokyo Chemical Industry Co. (Tokyo, Japan). Polyvinylidene fluoride (PVDF) membrane filter was obtained from Millipore Corp. (Bedford, MA, USA). Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).

High performance liquid chromatography (HPLC) analysis of YCTMT:

Hot water extract of YCTMT was prepared by dissolving it in methanol (5.0 mg/ml). Sample and standard solutions of glycyrrhizin were filtered through a filter cartridge (pore size of 0.22 μ m) prior to analysis. The chemical content quantification was

performed on a Shimadzu HPLC system equipped with Shimadzu LC-20AT pump, Shimadzu SIL-20 auto sampler, and Shimadzu SPD-M20A detector. The HPLC profile was performed on a RP-18 column (Cosmosil 5C18-AR-II, 4.6 \times 250 mm, 5 μ m) at a flow rate of 1.0 ml/min, detected at UV 254 nm. The injection volume was 10 μ l. The mobile phase was composed of 0.1% TFA water solution (A) and methanol (B). The solvent gradient was as follows: 0-60 min from 5% B to 55% B. By diluting the stock solution, a series of standard solutions (glycyrrhizin) were prepared with concentrations of 2, 1, 0.5, 0.25, 0.1, 0.05, and 0.025 mg/ml used to calculate the concentration of examined compounds.

Liquid chromatography tandem-mass spectrometry (LC-MS/MS) analysis of YCTMT:

LC-MS/MS experiments were performed on a Dionex Ultimate 3000 HPLC system (Dionex, Germany) coupled with an ESI-ion trap MS (HCTultra PTM Discovery, Bruker Daltonics, Germany). A linear gradient on a C18 LC column (Atlantis T3 C18 5 μ m 2.1 \times 150 mm) was used to separate the water extract of YCTMT with a flow rate of 0.25 ml/min. The mobile phase A consisted of water containing 0.1% v/v formic acid and mobile phase B containing 99.9% v/v acetonitrile and 0.1% v/v formic acid. A gradient elution was applied from 5% v/v B to 60% B in the first 25 min, and to 90% B over 5 min. It was then held at 90% B for another 4 min at the flow rate of 0.25 ml/min, which was followed by a return to the starting conditions and re-equilibration of the column for 5 min with 5% B v/v prior to the next injection. The ESI source was operated in positive or negative ion mode. Nitrogen was used as a nebulizing (45 psi) and drying gas (10 l/min, 350 $^{\circ}$). For the MS/MS settings, the most eight intense ions from each MS full scan spectrum were automatically selected as the precursor ion peaks for the following auto MS/MS experiments. Helium was used as the collision gas.

Cortical neuron cultures:

Sprague-Dawley rats were used to obtain primary cultures of cortical neurons. The protocols for animal experiments were performed according to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Experimental Committee of China Medical University under permit number: 96-113-C. Cultures of primary cortical neurons were prepared from cerebral cortices of 18 d-old embryonic rats^[13]. Briefly, pooled

dissected cerebral cortices were digested with papain solution and plated at a density of 8×10^5 cells/cm² on poly-D-lysine-coated dishes. One day after seeding, the culture medium was replaced with Neurobasal serum-free medium containing 1% B27 supplement, 0.5 mM l-glutamine, and 1% penicillin/streptomycin. Neurobasal serum-free medium was replaced every three days and 10 μ M cytosine arabinoside was added to the medium on the third day. The purity of primary neurons was over 95% and was employed between 12 to 14 d in culture.

Cell viability assays:

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium (MTT) reduction assay was used to monitor cell viability by measuring the mitochondrial succinic dehydrogenase activity as described previously^[14]. Experimental neuron cultures were either treated with 0-20 μ M of A β (1-40) alone for 24 h or first treated with various concentrations of YCTMT for 1 h followed by 10 μ M of A β (1-40) for 24 h. As for the positive control group, 1% Triton X-100 was added to the well, followed by 0.5 mg/ml MTT solution. After 24 h incubation, the quantity of formazan was determined by eluting with dimethyl sulfoxide and measured at 550 nm using a microplate reader (MR4000; Dynatech, Chantilly, VA). Eqn. 1: percent cell viability (%) = OD_{550} value of treated groups/ OD_{550} value of untreated control \times 100.

Western blot:

Cultures were washed twice with phosphate-buffered saline (PBS) and harvested in RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM sodium fluoride, 0.2 mM sodium orthovanadate, 1 μ g/ml leupeptin, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride). After centrifugation, the protein concentration in the supernatant was determined by Bradford assay. Protein extracts were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes. After blocking with 5% non-fat milk in PBS for 1 h, the membranes were washed with PBS containing 0.1% Tween-20 (PBST), and incubated at room temperature for 2 h with antibodies including β -amyloid, AchR, NMDAR1, NMDAR2, β -actin, and phosphorylated and non-phosphorylated forms of tau, respectively. Then the membranes were washed again and the horseradish peroxidase-labelled IgG was added at room temperature for 1 h. The blots were developed using enhanced chemiluminescence reagents^[15].

Measurement of intracellular ROS generation:

After YCTMT pretreatment, cultured neurons were incubated with 20 μ M 2,7-dichlorofluorescein-diacetate (DCFH-DA) for 30 min in the dark, then washed, and the intracellular content of ROS was measured by using the semi-quantitative fluorescence technique^[16] with a fluorescence microplate reader (Molecular Devices, CA, USA) at excitation/emission wavelengths of 400/505 nm. Results were expressed as fluorescence intensity.

Statistical analysis:

At least three independent experiments were performed as indicated in the figure legends. All data obtained were analysed using one-way analysis of variance (ANOVA) followed by post-hoc between-group analyses using Dunnett and Scheffé's test for multigroup comparisons and expressed as mean \pm standard deviation (SD). The criterion for statistical significance was $P < 0.05$ for all evaluations.

RESULTS AND DISCUSSION

The reference compound of glycyrrhizin was identified in YCTMT by HPLC, which acted as an indicator compound for quality check of extraction procedure of each batch (fig. 1). The content of glycyrrhizin was calculated to be 0.78 mg/ml of YCTMT by HPLC quantification. The components of YCTMT extract were identified by LC-MS/MS. According to the molecular weights of precursor ion and their corresponded fragment ions in MS/MS spectra referring to published literature. The base peak chromatogram (BPC) of positive and negative ions of the YCTMT extract by LC-MS/MS analysis was shown in fig. 2. Albiflorin, paeoniflorin, palmatine, berberine, daidzein, formononetin, gallic acid, caffeic acid, puerarin, ferulic acid, and glycyrrhizin were identified in YCTMT extract by LC-MS/MS analysis according to MS and MS/MS ions (Table 1).

The viability of primary cortical neurons was measured by MTT assay. As shown in fig. 3A, A β (1-40) reduced cell viability in a concentration-dependent manner, significant effect started at 5 μ M. Meanwhile, neurons incubated with various concentrations of YCTMT alone showed no significant effect on viability, even when the concentration of YCTMT was up to 320 μ g/ml. But neurons pretreated with YCTMT attenuated A β (1-40)-impaired cell viability in a concentration-dependent manner starting from 12.8 μ g/ml and up ($P < 0.05$) (fig. 3B).




Fig. 1: HPLC profile of YCTMT

(A) The chemical profile of the YCTMT was performed using a RP-18 column and detected at UV 254 nm, (B) HPLC chromatograms of the reference compound (glycyrrhizin, $t_R=36.692$ min)

To explore the protective effect of YCTMT on cortical neurons, the expression of β -amyloid and AchR was measured using western blot. As shown in fig. 4, administration of $A\beta(1-40)$ markedly increased the expression of β -amyloid as compared with the control. However, pre-incubation with YCTMT for 1 h inhibited the expression of β -amyloid in $A\beta(1-40)$ -stimulated cortical neurons in a concentration-dependent manner starting at 12.8 $\mu\text{g/ml}$ ($P<0.05$). Administration of $A\beta(1-40)$ for 4 h markedly reduced the expression of AchR as compared with the control. β -actin plays as a stable and constitutive internal control and has the same expression. With 1 h pre-incubation of YCTMT, the reduced expression of AchR in $A\beta(1-40)$ -stimulated cortical neurons was reversed in a concentration-dependent manner also starting at 12.8 $\mu\text{g/ml}$ ($P<0.05$). Administration of $A\beta(1-40)$ markedly reduced the expression of NMDAR1 and NMDAR2A as compared with the control. However, pre-incubated with YCTMT

for 1 h reversed the reduced expression of NMDAR1 and NMDAR2A in $A\beta(1-40)$ -stimulated cortical neurons in a concentration-dependent manner starting from 12.8 $\mu\text{g/ml}$ and up ($P<0.05$, fig. 5).

Administration of $A\beta(1-40)$ markedly induced intracellular ROS generation as compared with the control. β -actin plays as a stable and constitutive internal control and has the same expression, as shown in fig. 5. However, pre-incubated with YCTMT for 1 h inhibited intracellular ROS generation in $A\beta(1-40)$ -stimulated cortical neurons in a concentration-dependent manner, significant effect starting at 12.8 $\mu\text{g/ml}$ ($P<0.05$) (fig. 6). Administration of $A\beta(1-40)$ markedly induced phosphorylation of tau as compared with the control. However, pre-incubated with YCTMT for 1 h inhibited the phosphorylation of tau in $A\beta(1-40)$ -stimulated cortical neurons in a concentration-dependent manner, significant effect starting at 12.8 $\mu\text{g/ml}$ ($P<0.05$, fig. 7).




Fig. 2: The BPC of YCTMT extract by LC-MS/MS analysis
(A) Positive and (B) negative ions

TABLE 1: HPLC-MS-MS IDENTIFICATION OF THE CONSTITUENTS IN YCTMT EXTRACT

Peak no.	Selected ion	MS (ESI)	MS/MS (ESI)	Molecular formula	Proposed compound
1	$[M+H]^+$	481.2	319.2, 196.9	$C_{23}H_{28}O_{11}$	Albiflorin
2	$[M+NH_4]^+$	498.3	301.1, 178.9	$C_{23}H_{28}O_{11}$	Paeoniflorin
3	$[M]^+$	352.5	337.1, 308.1	$C_{21}H_{22}NO_4$	Palmatine
4	$[M]^+$	336.1	321.1, 292.1	$C_{20}H_{18}NO_4$	Berberine
5	$[M]^+$	254.1	198.9, 137.0	$C_{15}H_{10}O_4$	Daidzein
6	$[M+H]^+$	823.5	647.5, 453.4	$C_{42}H_{62}O_{16}$	Glycyrrhizin
7	$[M]^+$	268.3	254.0, 237.0, 213.0	$C_{16}H_{12}O_4$	Formononetin
8	$[M-H]^-$	169	125.0	$C_7H_6O_5$	Gallic acid
9	$[M-H]^-$	415.2	295.1, 267.0	$C_{21}H_{20}O_9$	Puerarin
10	$[M-H]^-$	179.1	135.0	$C_9H_8O_4$	Caffeic acid
11	$[M-H]^-$	193.0	177.9, 149.0, 134.0	$C_{10}H_{10}O_4$	Ferulic acid
12	$[M-H]^-$	821.5	627.1, 361.1	$C_{42}H_{62}O_{16}$	Glycyrrhizin




Fig. 3: Effects of YCTMT on A β (1-40)-reduced cell viability
Cell viability was measured by MTT assay. Data are expressed as mean \pm SD (n=4). *P<0.05 was considered significant as compared with the vehicle values. ■ With amyloid beta; □ without amyloid- β

YCTMT is one of the most important traditional Chinese medicines and widely used in Asian countries such as China, Japan, and Korea. However, there are several pieces of evidence, which demonstrate that some of the YCTMT composites, such as *A. membranaceus* (Fisch.) Bunge, *G. quinquefolium* (L.) Alph. Wood, *P. lobata* (Willd.) Ohwi, and *G. uralensis*, have the ability to protect against AD^[17-20]. Moreover, YCTMT improves A β (1-40)-induced AD-like phenotype, including learning and memory loss^[12]. The death of neuron in cerebral cortex is an important feature of AD^[3]. In the present study, we also found A β (1-40), the most abundant of A β isoform-induced cytotoxicity in primary cortical neurons. Though YCTMT alone has no effect on cell viability of cortical neurons, A β (1-40)-induced neuron death is inhibited by pretreatment of YCTMT in a concentration-dependent manner. These results suggested that AD could be improved by YCTMT via reduced death of cortical neuron.

The imbalance between clearance and production of A β causes its intracellular accumulation, which is the initiating factor of AD. These accumulated intracellular A β will further deposit and assemble

into fibrils, which arrange themselves into parallel β -pleated sheets to form insoluble plaques^[8]. These A β plaques are the conspicuous pathological feature in brains of AD patients. In addition, there are evidences proposed that among the A β isoforms, A β (1-40) and A β (1-42) are the most toxic species. In AD caused by APP gene duplication, the intracellular A β (1-40) has shown prominent existence in patients' neurons^[21,22]. Murine model of AD showed that intracellular A β accumulation results in neuron death^[23]. At present, we had demonstrated the increased expression of A β in A β (1-40)-treated primary cortical neurons, and which was attenuated by YCTMT in a dose-dependent manner. These results were in accordance with pervious study, which demonstrated that A β plague accumulation was reduced by YCTMT in brain of A β (1-40)-induced AD rats^[12]. In addition, the A β -induced toxic effect appeared more rapidly on cholinergic axon terminals than on cell bodies^[24]. The activation of choline acetyltransferase and acetylcholinesterase are significantly reduced in AD patients^[25]. In A β (1-40)-induced AD rats, the




Fig. 4: Effect of YCTMT on A β (1-40)-induced accumulation of β -amyloid and down-regulation of AchR

Values were expressed as mean \pm SD (n=3 in each group). *P<0.05 was considered significant as compared with the A β (1-40) values. C T: control; Y 1: YCMT (12.8 μ g/ml); Y 2: YCMT (64 μ g/ml); Y 3: YCMT (320 μ g/ml); A 1: Amyloid- β (10 μ M)




Fig. 5: Effect of YCTMT on A β (1-40)-induced down-regulation of NMDAR1 and NMDAR2A

Values were expressed as mean \pm SD (n=3 in each group). *P<0.05 was considered significant as compared with the A β (1-40) values. CT: control; Y 1: YCMT (12.8 μ g/ml); Y 2: YCMT (64 μ g/ml); Y 3: YCMT (320 μ g/ml); A 1: Amyloid- β (10 μ M)




Fig. 6: Effect of YCTMT on A β (1-40)-induced intracellular ROS generation

Values were expressed as mean \pm SD (n=5). #P<0.05 was considered significant as compared with the vehicle values (CT). *P<0.05 was considered significant as compared with the A β (1-40) values. CT: control; Y 1: YCMT (12.8 μ g/ml); Y 2: YCMT (64 μ g/ml); Y 3: YCMT (320 μ g/ml); A 1: Amyloid- β (10 μ M)

expression of acetylcholine in brain was recovered by YCTMT^[12]. The results of present study indicated that the A β (1-40)-induced AchR expression was inhibited by YCTMT in primary cortical neurons. All these

data gathered had made it clear that YCTMT could improve A β -induced neuronal death via reduction of A β accumulation and increased AchR expression.

NMDARs are the glutamate-gated cation channels with high calcium permeability and widely expressed in the central nervous system and play an important role in both excitatory synaptic transmission under physiological conditions and excitotoxic neuronal death under pathological conditions^[26]. NMDARs are tetrameric complexes form by several heteromeric complexes from three NMDAR classes and their various subunits, which are NMDAR1, NMDAR2 with subunits A, B, C, and D, and NMDAR3 with subunits A and B. NMDAR1/2A, the di-heteromeric component of NMDARs, is widely and abundantly expressed in CNS in the mammalian^[27]. It has been demonstrated that during the progression process of AD, mRNA and DNA expression of NMDAR1 subunit was down regulated in human^[28]. In AD, NMDAR1 containing an N-terminal splice cassette appears to be reduced significantly, which may result in susceptible cells accession^[29]. In the hippocampus and cortex of post-mortem brain from AD patients, levels of NMDAR2A mRNA and protein similar to NMDAR1 are also decreased^[30]. It was found that while the expression of NMDAR1/2A was reduced by A β (1-40) in primary cortical neurons, pretreatment with YCTMT reversed the effect in a dose-dependent manner. These




Fig. 7: Effect of YCTMT on A β (1-40)-induced phosphorylation of tau

Values were expressed as mean \pm SD (n=3 in each group). #P<0.05 was considered significant as compared with the vehicle values (CT). *P<0.05 was considered significant as compared with the A β (1-40) values. CT: control; Y 1: YCMT (12.8 μ g/ml); Y 2: YCMT (64 μ g/ml); Y 3: YCMT (320 μ g/ml); A 1: Amyloid- β (10 μ M)

results indicated that YCTMT could improve A β -induced neuronal death via destructing the diminishing expression of NMDAR1/2A.

Excessive activation of NMDARs is stimulated by A β , which in turn leads to calcium influx. The abnormally increased concentration of calcium in cytosol and mitochondria leads to mitochondria disruption. In addition, intracellular A β causes damage to cytochrome *c* oxidase, α -ketoglutarate and pyruvate dehydrogenase, and DNA in mitochondria. Therefore, A β directly or indirectly harms the mitochondrial functions and results in overproduction of ROS^[8,31]. Oxidative stress generated from these ROS plays an important role in A β -induced excitotoxicity^[32]. A β -induced generation of oxidative stress is inhibited by NMDAR inhibitors^[33]. It was found that the generation of ROS was stimulated by A β (1-40) in primary cortical neurons, while pretreatment with YCTMT reversed the effect in a dose-dependent manner. These results indicated that YCTMT could improve A β -induced excitotoxicity via reducing the generation of oxidative stress.

Tau, the highly soluble microtubule-associated protein, promotes tubulin assembly into microtubules and stabilizes formed microtubules^[34]. There are several critical phosphorylation sites on serine, threonine, and tyrosine residues for regulating the affinity of microtubules^[34,35]. Normally, tau stabilizes microtubule structure, but such stabilization is converted into disruption when hyper phosphorylation of tau is induced by several kinases, including glycogen synthase kinase-3 β , cyclin-dependent kinase-5, mitogen-activated protein kinase, Akt, Fyn, protein kinase A, calcium-calmodulin protein kinase 2, and microtubule affinity-regulating kinase^[36]. The sites of hyperphosphorylation on tau form paired helical filaments, which result in neurofibrillary lesions in brains of AD patients^[8]. It has been proposed that phosphorylation of tau is induced by A β in cortical neurons^[37]. It was demonstrated that A β (1-40)-induced tau phosphorylation in primary cortical neurons, of which neurons treated with YCTMT alone has no effect. On the other hand, pretreatment with YCTMT reversed the A β (1-40)-induced tau phosphorylation in a dose-dependent manner. The evidence suggested that A β -induced hyper phosphorylation of tau via NMDAR activation through glycogen synthase kinase-3 β , and the positive feedback from hyper phosphorylation of tau activated the NMDAR via tyrosine kinase, Fyn^[38]. All these results indicated that YCTMT could improve

A β -induced excitotoxicity via the reduction of tau phosphorylation.

In present study, we have demonstrated that YCTMT effectively attenuates A β -induced neuronal death. The mechanisms underlying this protective effect include improvement of β -amyloid accumulation and AchR reduction; reversal of NMDAR1 and NMDAR2A expression; reduction of intracellular ROS generation; and inhibition of tau phosphorylation. Experimental findings support the potential use of YCTMT as a therapeutic agent for AD prevention. However, A β (1-42) is the other toxic species in AD. The further study about A β (1-42)-induced neurocytotoxicity reduced by YCTMT will be more confirm the hypothesis.

Acknowledgments:

Authors express their gratitude to Prof. Hsieh Ming-Tsuen of the Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan for identifying and certifying the plant material used. This study was supported by the Show Chwan Memorial Hospital, Changhua, Taiwan (Grant: RD99008, RD98017, RD103013) and Ministry of Science and Technology of Taiwan (MOST 103-2314-B-212-001-).

Conflict of interest:

All authors declare no conflict of interests.

Financial support:

Nil.

REFERENCES

1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, *et al.* Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* 2012;367:795-804.
2. Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, *et al.* Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. *Alzheimers Dement* 2011;7:80-93.
3. Franco R, Cedazo-Minguez A. Successful therapies for Alzheimer's disease: why so many in animal models and none in humans? *Front Pharmacol* 2014;5:146.
4. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med* 2011;1:a006189.
5. Hsieh MT, Peng WH, Wu CR, Ng KY, Cheng CL, Xu HX. Review on experimental research of herbal medicines with anti-amnesic activity. *Planta Med* 2010;76:203-17.
6. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. *Neuron* 1996;16:921-32.

7. Benilova I, Karran E, De Strooper B. The toxic A β oligomer and Alzheimer's disease: an emperor in need of clothes. *Nat Neurosci* 2012;15:349-57.
8. Querfurth HW, LaFerla FM. Alzheimer's disease. *N Engl J Med* 2010;362:329-44.
9. Li Y. Effect of *Yi-Qi-Tsung-Ming-Tang* and its derived formula on tinnitus and deafness on 68 cases. *Yunnan J Tradit Chin Med Mater Med* 2013;4:87.
10. Gao XG, Liu J. Effect of *Yi-Chi-Tsung-Ming-Tang* and its derived formula on symptoms of conscious aging diseases. *J Pract Tradit Chin Int Med* 2007;4:60.
11. Gui MJ, Bao YC, Zhang B. Effect of *Yi-Chi-Tsung-Ming-Tang* and its derived formula on neurology diseases. *Clin J Tradit Chin Med* 2012;3:260-2.
12. Yeh CH, Hsieh MT, Hsueh CM, Wu CR, Huang YC, Liao JW, *et al.* Therapeutic effect of *Yi-Chi-Tsung-Ming-Tang* on amyloid beta-induced Alzheimer's disease-like phenotype via an increase of acetylcholine and decrease of amyloid beta. *Evid Based Complement Alternat Med* 2012;2012:414536.
13. Chen CJ, Chen JH, Chen SY, Liao SL, Raung SL. Upregulation of RANTES gene expression in neuroglia by Japanese encephalitis virus infection. *J Virol* 2004;78:12107-19.
14. Huang FM, Kuan YH, Lee SS, Chang YC. Cytotoxicity and genotoxicity of triethyleneglycol-dimethacrylate in macrophages involved in DNA damage and caspases activation. *Environ Toxicol* 2015;30:581-8.
15. Huang FM, Chang YC, Lee SS, Yeh CH, Lee KG, Huang YC, *et al.* BisGMA-induced cytotoxicity and genotoxicity in macrophages are attenuated by wogonin via reduction of intrinsic caspase pathway activation. *Environ Toxicol* 2016;31:176-84.
16. Lin RH, Yang ML, Li YC, Chang HM, Kuan YH. Indium chloride-induced micronuclei via reactive oxygen species in Chinese hamster lung fibroblast V79 cells. *Environ Toxicol* 2013;28:595-600.
17. Sun M, Zhou T, Zhou L, Chen Q, Yu Y, Yang H, *et al.* Formononetin protects neurons against hypoxia-induced cytotoxicity through upregulation of ADAM10 and sA β PP α . *J Alzheimers Dis* 2012;28:795-808.
18. Choi RC, Zhu JT, Leung KW, Chu GK, Xie HQ, Chen VP, *et al.* A flavonol glycoside, isolated from roots of *Panax notoginseng*, reduces amyloid-beta-induced neurotoxicity in cultured neurons: signaling transduction and drug development for Alzheimer's disease. *J Alzheimers Dis* 2010;19:795-811.
19. Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. *J Alzheimers Dis* 2013;33:S123-39.
20. Ahn J, Um M, Choi W, Kim S, Ha T. Protective effects of *Glycyrrhiza uralensis* Fisch. on the cognitive deficits caused by beta-amyloid peptide 25-35 in young mice. *Biogerontology* 2006;7:239-47.
21. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, *et al.* APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. *Nat Genet* 2006;38:24-6.
22. Cabrejo L, Guyant-Maréchal L, Laquerrière A, Vercelletto M, De la Fournière F, Thomas-Antérion C, *et al.* Phenotype associated with APP duplication in five families. *Brain* 2006;129:2966-76.
23. Magrane J, Rosen KM, Smith RC, Walsh K, Gouras GK, Querfurth HW. Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. *J Neurosci* 2005;25:10960-9.
24. Kasa P Sr., Papp H, Kasa P Jr., Pakaski M, Balaspiri L. Effects of amyloid-beta on cholinergic and acetylcholinesterase-positive cells in cultured basal forebrain neurons of embryonic rat brain. *Brain Res* 2004;998:73-82.
25. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. *Br Med J* 1978;2:1457-9.
26. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. *Curr Opin Pharmacol* 2007;7:39-47.
27. Tackenberg C, Grinschgl S, Trutzel A, Santucci AC, Frey MC, Konietzko U, *et al.* NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. *Cell Death Dis* 2013;4:e608.
28. Jacob CP, Koutsilieris E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, *et al.* Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. *J Alzheimers Dis* 2007;11:97-116.
29. Hynd MR, Scott HL, Dodd PR. Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease. *J Neurochem* 2004;89:240-7.
30. Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomic MD, Wolfe BB, Armstrong DM. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. *Neurobiol Dis* 2004;15:80-92.
31. Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. *Nat Neurosci* 2010;13:812-8.
32. Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease. *J Alzheimers Dis* 2010;19:341-53.
33. Parks JK, Smith TS, Trimmer PA, Bennett JP Jr, Parker WD Jr. Neurotoxic A β peptides increase oxidative stress *in vivo* through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition *in vitro*. *J Neurochem* 2001;76:1050-6.
34. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. *Physiol Rev* 2004;84:361-384.
35. Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. *J Neurosci* 2002;22:10-20.
36. Wang K, Zhu L, Zhu X, Zhang K, Huang B, Zhang J. Protective effect of paeoniflorin on A β 25-35-induced SH-SY5Y cell injury by preventing mitochondrial dysfunction. *Cell Mol Neurobiol* 2014;34:227-34.
37. Kim EA, Cho CH, Hahn HG, Choi SY, Cho SW. 2-cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride protects against beta-amyloid-induced activation of the apoptotic cascade in cultured cortical neurons. *Cell Mol Neurobiol* 2014;34:963-72.
38. Mondragón-Rodríguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, *et al.* Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. *J Biol Chem* 2012;287:32040-53.